Malin has named Andrew von Eschenbach, M.D., as its chief medical adviser. The appointment puts the former FDA commissioner in a position to work with Immunocore, Poseida Therapeutics and the other cancer biotechs Malin has backed.
Von Eschenbach has worked with Malin since around the time Kelly Martin and other former Elan executives set up the fund and pulled off a €330 million ($390 million) IPO in 2015. But that earlier position on Malin’s scientific advisory board limited the extent to which von Eschenbach worked with the fund’s management team and portfolio companies.
Malin’s appointment of von Eschenbach as chief medical adviser will see the man who ran the FDA from 2006 to 2009 take a more active role in its activities, particularly those relating to its oncology and immuno-oncology investments.
Biotechs in these fields represent some of the biggest bets made by Malin so far. The Irish VC shop has invested more than €70 million in British immuno-oncology star Immunocore and a further €27 million in West Coast CAR-T and gene therapy startup Poseida.
With Immunocore’s lead candidate now in a pivotal trial and Poseida’s BCMA CAR-T in the clinic, a man with von Eschenbach’s background could prove useful.
“Now is a great time for me to join in a formal role as the portfolio continues to mature towards clinical and regulatory milestones,” von Eschenbach said in a statement.
Malin needs Immunocore and Poseida to plot a smoother course past these milestones than some of its other bets have managed. The fair value of most of Malin’s investments is equal or slightly above the amount it put into the companies. But the fund’s performance is marred by Novan and Serenus.
The combined fair value of Malin’s investments in the two companies stood at €16.2 million as of the end of June. Malin has invested €59.6 million in the two companies. The fund’s share price is down close to 20% over the past year.
Martin took over as CEO of Novan in June after the company was rocked by late-phase setbacks. At the end of last month, Martin stepped down as CEO of Malin to spend more time working with some of its portfolio companies, including Novan and Poseida.
By Nick Paul Taylor
Source: Fierce Biotech
The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).
“If in 2005 someone told you that two-thirds of our industry would be driven on the R&D side by emerging biopharma—it would be unthinkable. If one were to project that trend forward, what it would suggest is that we could have a day when we do this talk, say in 2027 or 2028, where 80% of the industry’s pipeline is coming from emerging companies.”
The German healthcare and agrochemicals giant told Reuters that in future its pharma pipeline will focus on cardiovascular disease, neurology, rare diseases and immunology, while de-emphasizing women’s health, a field it first focused on with the acquisition of the former women’s health specialist Schering in 2006.
